Entero Therapeutics, Inc. (ENTO)
Automate Your Wheel Strategy on ENTO
With Tiblio's Option Bot, you can configure your own wheel strategy including ENTO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENTO
- Rev/Share 0.0
- Book/Share 12.159
- PB 0.0405
- Debt/Equity 0.0024
- CurrentRatio 3.0305
- ROIC -0.2718
- MktCap 2344739.0
- FreeCF/Share -1.9389
- PFCF -0.2544
- PE -0.1295
- Debt/Assets 0.0016
- DivYield 0
- ROE -0.2612
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Published: March 24, 2025 by: Newsfile Corp
Sentiment: Neutral
Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business Combination which was previously announced on December 18, 2023 and ultimately closed on March 14, 2024. The Rescission Agreement and its effects are subject to certain closing conditions, including Entero receiving shareholder approval which must …
Read More
Entero Therapeutics Appoints Richard Paolone as CEO
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company.
Read More
About Entero Therapeutics, Inc. (ENTO)
- IPO Date 2016-10-11
- Website https://www.firstwavebio.com
- Industry Biotechnology
- CEO Ms. Anna Skowron
- Employees 2